Axcan Acquires Photofrin Rights from QLT
MONT SAINT-HILAIRE, Quebec, Canada, May 2 -- Axcan Pharma Inc. has signed an agreement to acquire worldwide rights to Photofrin -- a drug approved for use in photodynamic therapy for the treatment of certain cancers -- from QLT PhotoTherapeutics Inc. (QLT) of Vancouver.
Axcan's acquisition of the rights to the drug involves a stock subscription agreement under which QLT will purchase 1,283,333 shares of Axcan common stock for $19,250,000 (CDN), or $15 per share (CDN). The transaction between the two companies also involves an asset purchase agreement, which calls for QLT to sell, license or sub-license to Axcan all QLT's rights, title and interest in Photofrin for $39.25 million (CDN). This agreement includes the sale of QLT's European subsidiary, which owns the European registrations for Photofrin.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024